To request a trial version of ChemDraw, click here.
Signals ChemDraw Trial is valid for 15 days. There are no individual trials for ChemDraw Prime or ChemDraw Professional.
You will need to use a company email address to register. Personal email addresses such as Gmail, Hotmail, etc., will not work to register for a trial.
Once you subscribe, you will receive an email about how to access the Signals ChemDraw Tenant. Follow the instructions to set up your password and access the portal.
This email is sent up to 72 hours after registering. International customers could experience additional delays due to trade compliance regulations. If you do not receive anything, try submitting your request a second time.
Access your Signals system using the tenant URL https://signalstrial.signalsresearch.revvitycloud.eu
Use your email address as your user ID.
If you have issues logging in, use the forgot password option as indicated above on the login page to reset it. Once logged in you will see the home page like below.
Before being launchable, ChemDraw Desktop software and ChemDraw Collections must first be installed and authenticated using the trial tenant URL. To install, navigate to Installers at the home page of the tenant.
To install ChemDraw Desktop and ChemDraw Collections, use the 1st installer for installation.
If You want to test applications like ChemDraw for Excel, Chem3D, ChemFinder and ChemScript, please download ChemDraw Applications installer (4th installer) and install it and authenticate using the trial tenant URL.
Once installed, ChemDraw Desktop software and other applications can be launched from the start - All Apps menu of your machine.
ChemDraw and other applications will be authenticated like below. Click on sign in and use your login credentials to authenticate.
Note: ChemDraw for Excel, Chem3D, ChemFinder and ChemScript are not available as trial for Mac users. Mac users can use ChemDraw Desktop software, ChemDraw Collections and ChemDraw+. ChemDraw+ is a cloud based ChemDraw application.
Comments
0 comments
Article is closed for comments.